Alloy Therapeutics has developed a drug discovery platform designed to support and expedite antibody discovery projects. The company's innovative technology includes humanized transgenic antibody discovery, which offers wide, non-exclusive access to drug discovery tools. This empowers scientists to carry out their antibody projects without any difficulty.

Investors Include:

Tony Eng, Massachusetts Life Sciences Center, Jesse Robbins, Founders Fund, Calm Ventures, 8VC, 10X Capital, Alexandria Venture Investments, Jonathan Harshman, Luma Bio-IT Management, New Silk Route Growth Capital, Thiel Capital, Adam Groff, Ulysses Diversified Holding, Gaingels, Kent Mabalay, OurCrowd, Peter Thiel, Mubadala Capital, Presight Capital.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Learn more

Our available services for this company

Lifetime IncomeCharitable Remainder Trust

Tax SavingsDonor Advised Fund